Delivering focused radiation therapy over three to five sessions after surgery for a large brain metastasis reduced the risk of cancer returning at the surgical site compared with delivering the radiation in a single session, according to the results of the Alliance for Clinical Trials in Oncology A071801 presented today at the plenary session of the American Society for Radiation Oncology in Boston.

Gastric cancer remains a major global health challenge, and therapeutic resistance continues to limit the effectiveness of existing HER2-targeted treatments. A research team from Jiangsu University has developed a bispecific cellular nanovesicle platform that simultaneously targets CD16-positive natural killer (NK) cells and HER2-positive gastric cancer cells. The engineered nanovesicles enhance NK cell recruitment, activation, cytokine secretion, and tumor-killing activity, providing a promising strategy for next-generation cancer immunotherapy.

BUFFALO, NY – September 28, 2026 – A new editorial was published in Volume 17 of Oncotarget on September 23, 2026, titled “Gut feeling: Microbes at the heart of cancer therapy.” 

The development of treatment resistance is one of the key challenges in modern cancer and antibiotic therapy. New therapeutic approaches aim to curb the spread of resistance through the targeted timing of treatment cycles. Researchers at the Max-Planck-Zentrum für Physik und Medizin (MPZPM) have now demonstrated how a deeper understanding of the physical processes occurring in growing tumors and microbial biofilms can contribute to the success of “evolution-based” therapies.

An international research team has discovered that the protein HERC4 is a key component in the signalling pathways involved in programmed cell death, which is responsible for triggering inflammatory diseases. The discovery will potentially lead the way to new therapeutic approaches for chronic inflammatory bowel diseases, rheumatism and psoriasis, as well as for inflammation-related types of cancer / Publication in ‘Nature Structural and Molecular Biology’

A new clinical trial published in the Chinese Medical Journal has assessed a novel triple-combination regimen comprising the angiogenesis inhibitors famitinib, the cyclin-dependent kinase 4/6 (CDK4/6) inhibitor dalpiciclib, and fulvestrant for the treatment of hormone receptor-positive, human epidermal growth factor receptor 2-negative (HR+/HER2−) advanced breast cancer. Although the regimen exhibited measurable antitumor activity, its overall efficacy and safety profile did not support its use as a preferred first-line therapeutic option.